228 related articles for article (PubMed ID: 37458897)
1. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.
Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
Neurol Ther; 2023 Oct; 12(5):1709-1728. PubMed ID: 37458897
[TBL] [Abstract][Full Text] [Related]
2. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.
Nicholas JA; Gudesblatt M; Garabedian M; Belviso N; Shen C; Geremakis C; Shankar SL; Mendoza JP; Lewin JB
Mult Scler Relat Disord; 2022 Jul; 63():103921. PubMed ID: 35700674
[TBL] [Abstract][Full Text] [Related]
3. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
4. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
[No Abstract] [Full Text] [Related]
5. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
Foong YC; Merlo D; Gresle M; Buzzard K; Zhong M; Yeh WZ; Jokubaitis V; Monif M; Skibina O; Ozakbas S; Patti F; Grammond P; Amato MP; Kalincik T; Horakova D; Kubala Havrdova E; Weinstock-Guttman B; Lechner Scott J; Boz C; Sa MJ; Butzkueven H; van der Walt A; Zhu C;
J Neurol Neurosurg Psychiatry; 2024 Mar; ():. PubMed ID: 38453478
[TBL] [Abstract][Full Text] [Related]
6. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States.
Nicholas J; Halpern R; Ziehn M; Peterson-Brandt J; Leszko M; Deshpande C
J Med Econ; 2020 Aug; 23(8):885-893. PubMed ID: 32338098
[No Abstract] [Full Text] [Related]
7. Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis.
Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
Drugs Real World Outcomes; 2023 Dec; 10(4):565-575. PubMed ID: 37733192
[TBL] [Abstract][Full Text] [Related]
8. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data.
Amezcua L; Livingston T; Hayward B; Zhou J; Williams MJ
Mult Scler Relat Disord; 2023 Sep; 77():104866. PubMed ID: 37487345
[TBL] [Abstract][Full Text] [Related]
9. Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study.
Meltzer E; Charron O; Wozny J; Onuorah H; Montague A; Kline AC; Largent A; Krause TM; Freeman L
Mult Scler Relat Disord; 2023 Dec; 80():105085. PubMed ID: 37931487
[TBL] [Abstract][Full Text] [Related]
10. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
[TBL] [Abstract][Full Text] [Related]
11. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
[No Abstract] [Full Text] [Related]
12. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
[TBL] [Abstract][Full Text] [Related]
13. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.
Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
Mult Scler Relat Disord; 2023 Jan; 69():104456. PubMed ID: 36529068
[TBL] [Abstract][Full Text] [Related]
14. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies.
Alvarez E; Nair KV; Tan H; Rathi K; Gabler NB; Maiese EM; Deshpande C; Shao Q
J Med Econ; 2023; 26(1):494-502. PubMed ID: 36970763
[TBL] [Abstract][Full Text] [Related]
15. Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA.
Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
J Comp Eff Res; 2023 Jan; 12(1):e220127. PubMed ID: 36440609
[No Abstract] [Full Text] [Related]
16. Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States.
Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
Clinicoecon Outcomes Res; 2023; 15():361-373. PubMed ID: 37234086
[TBL] [Abstract][Full Text] [Related]
17. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Freeman L; Kee A; Tian M; Mehta R
Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
[TBL] [Abstract][Full Text] [Related]
19. The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis.
Pardo G; Pineda ED; Ng CD; Sheinson D; Bonine NG
J Health Econ Outcomes Res; 2022; 9(1):111-116. PubMed ID: 35586512
[No Abstract] [Full Text] [Related]
20. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
Frahm N; Ellenberger D; Stahmann A; Fneish F; Lüftenegger D; Salmen HC; Schirduan K; Schaak TPA; Flachenecker P; Kleinschnitz C; Paul F; Krefting D; Zettl UK; Peters M; Warnke C
Ther Adv Neurol Disord; 2024; 17():17562864241239740. PubMed ID: 38560408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
